JP2002322062A - Liquid preparation for oral administration - Google Patents
Liquid preparation for oral administrationInfo
- Publication number
- JP2002322062A JP2002322062A JP2002040132A JP2002040132A JP2002322062A JP 2002322062 A JP2002322062 A JP 2002322062A JP 2002040132 A JP2002040132 A JP 2002040132A JP 2002040132 A JP2002040132 A JP 2002040132A JP 2002322062 A JP2002322062 A JP 2002322062A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- liquid preparation
- vitamin
- derivatives
- liquid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Abstract
Description
【０００１】[0001]
【発明の属する技術分野】本発明は風味の改善された複
合ビタミン内服用液剤に関し、さらに詳細には、有効成
分としてビタミンＢ群またはその誘導体を含有する保存
安定性に優れた、食品、医薬品または医薬部外品として
の内服用液剤に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a liquid preparation for oral administration of a complex vitamin having an improved flavor. More specifically, the present invention relates to a food, pharmaceutical or pharmaceutical composition containing a vitamin B group or a derivative thereof as an active ingredient and having excellent storage stability. The present invention relates to a liquid medicine for internal use as a quasi drug.
【０００２】[0002]
【従来の技術】ビタミンＢ群またはその誘導体は苦味が
あり、服用しにくいことはよく知られた事実である。こ
れを改善するために、従来のビタミンＢ含有内服用液剤
にはショ糖（白糖）、蜂蜜を配合しても服用後に苦味が
残ることから、アミノ酸とアップル系香料を配合したり
（特開平５−４９２１号）、精油または精油成分を配合
したりしている（特開平５−２５５１２６号）。また、
ビタミンＢ１誘導体にカンゾウおよび非イオン性界面活
性剤を添加したり（特開平９−３２８４２９号）、チア
ミンまたはその塩を配合した液剤に、ジンジャー系香料
を添加して（特開平１１−２０９２６６号）、苦味を低
減している。2. Description of the Related Art It is a well-known fact that B vitamins or derivatives thereof are bitter and difficult to take. In order to improve this, conventional amino acids containing vitamin B contain bitterness after ingestion even when sucrose (sucrose) and honey are added. No. 4921), and essential oils or essential oil components (Japanese Patent Laid-Open No. 5-255126). Also,
Vitamin B 1 derivatives may be added to liquorice and non-ionic surfactant (JP-A-9-328429), the liquid formulated with thiamine or a salt thereof, with the addition of ginger fragrance (JP-A-11-209266 ), Reducing bitterness.
【０００３】[0003]
【発明が解決しようとする課題】本発明は、ビタミンＢ
群またはその誘導体を含有する液剤の風味改善を目的と
する。SUMMARY OF THE INVENTION The present invention relates to vitamin B
The purpose is to improve the flavor of a liquid preparation containing a group or a derivative thereof.
【０００４】[0004]
【課題を解決するための手段】本発明者らは種々検討し
た結果、転化型液糖がビタミンＢ群またはその誘導体の
苦味を特異的に低減させることを見出し、本発明を完成
するに至った。すなわち、本発明は、（１）ビタミンＢ
群またはその誘導体を配合した液剤において、転化型液
糖を配合することにより苦味が低減された内服用液剤、
（２）ビタミンＢ群またはその誘導体が、チアミンおよ
びその誘導体、リボフラビンおよびその誘導体、ピリド
キシンおよびその誘導体、ビタミンＢ１２およびその誘
導体ならびにそれらの薬学的に許容される塩から選択さ
れる１種または２種以上のものである上記（１）記載の
内服用液剤、（３）ビタミンＢ群またはその誘導体がチ
アミン、その誘導体またはその薬学的に許容される塩か
ら選択される上記（１）１記載の内服用液剤、（４）フ
ルスルチアミンを含有する上記（１）記載の内服用液
剤、（５）転化型液糖の配合比率が液剤全量に対して５
〜３０重量％である上記（１）〜（４）いずれか１項記
載の内服用液剤、（６）液剤のｐＨが２〜７の範囲であ
る上記（１）〜（５）いずれか１項記載の内服用液剤、
および（７）さらに有機酸または無機酸を配合した上記
（１）〜（６）のいずれか１項記載の内服用液剤を提供
するものである。As a result of various studies, the present inventors have found that invertable liquid sugar specifically reduces the bitter taste of the vitamin B group or a derivative thereof, and have completed the present invention. . That is, the present invention provides (1) vitamin B
In a liquid preparation containing a group or a derivative thereof, a liquid preparation for internal use in which bitterness has been reduced by compounding invert type liquid sugar,
(2) B vitamins or derivatives thereof, thiamine and its derivatives, riboflavin and its derivatives, pyridoxine and its derivatives, vitamin B 12 and one or selected from a derivative thereof and pharmaceutically acceptable salts their pharmaceutically (1) The liquid medicine for internal use according to the above (1), wherein the vitamin B group or a derivative thereof is selected from thiamine, a derivative thereof, or a pharmaceutically acceptable salt thereof. The liquid preparation for internal use, (4) the liquid preparation for oral use according to the above (1) containing fursultiamine, and (5) the mixing ratio of the invertable liquid sugar is 5 to the total amount of the liquid preparation.
The liquid medicine for internal use according to any one of the above (1) to (4), wherein the pH of the liquid medicine is in the range of 2 to 7; Liquid medicine for internal use described,
And (7) The liquid medicine for internal use according to any one of (1) to (6), further comprising an organic acid or an inorganic acid.
【０００５】[0005]
【発明の実施の形態】本発明の内服用液剤で用いるビタ
ミンＢ群およびその誘導体は、この種の液剤に通常用い
られるものいずれでもよく、例えば、チアミン、チアミ
ンの薬学的に許容される塩（例、チアミン塩酸塩、チア
ミン硝酸塩等）、チアミン誘導体（例、プロスルチアミ
ン、フルスルチアミン、オクトチアミン、アリチアミ
ン、チアミンジスルフィド、Ｏ−ベンゾイルチアミンジ
スルフィド、チアミンモノホスフェートジスルフィド、
Ｏ，Ｓ−ジベンゾイルチアミン、Ｓ−ベンゾイルチアミ
ン、ベンホチアミン、ジセチアミン、ジクロカルボチア
ミン等）、チアミン誘導体の薬学的に許容される塩
（例、塩酸塩、硝酸塩、リン酸、硫酸塩等の酸付加
塩）、リボフラビン、リボフラビン誘導体（例、酪酸リ
ボフラビン、リン酸リボフラビンナトリウム等）、ピリ
ドキシン、ピリドキシンの薬学的に許容される塩（例、
ピリドキシン塩酸塩等）、ピリドキシン誘導体（例、ピ
リドキサルリン酸、ピリドキサミンリン酸等）、ビタミ
ンＢ１２（例、シアノコバラミン、ヒドロキソコバラミ
ン、酢酸ヒドロキシコバラミン、メチルコバラミン等）
等から選ばれる１種または２種以上が挙げられる。BEST MODE FOR CARRYING OUT THE INVENTION The vitamin B group and its derivatives used in the liquid preparation for internal use according to the present invention may be any of those usually used in this kind of liquid preparation, for example, thiamine, a pharmaceutically acceptable salt of thiamine ( E.g., thiamine hydrochloride, thiamine nitrate, etc., thiamine derivatives (e.g., prosultiamine, fursultiamine, octiamine, alitiamine, thiamine disulfide, O-benzoyl thiamine disulfide, thiamine monophosphate disulfide,
O, S-dibenzoylthiamine, S-benzoylthiamine, benfotiamine, dicetiamine, diclocarbothiamine, and the like, and pharmaceutically acceptable salts of thiamine derivatives (eg, hydrochloride, nitrate, phosphoric acid, sulfate, and other acid additions) Salts), riboflavin, riboflavin derivatives (eg, riboflavin butyrate, sodium riboflavin phosphate), pyridoxine, pharmaceutically acceptable salts of pyridoxine (eg,
Pyridoxine hydrochloride, etc.), pyridoxine derivatives (eg, pyridoxal phosphate, pyridoxamine phosphate, etc.), vitamin B 12 (eg, cyanocobalamin, hydroxocobalamin, hydroxycobalamin acetate, methylcobalamin, etc.)
And one or more selected from the above.
【０００６】本発明で用いる転化型液糖は、サトウキビ
やビートの搾汁を濃縮し、ショ糖分を結晶させ、取り出
した原料粗糖から製造される。この粗糖を溶解し、活性
炭（骨炭）やイオン交換樹脂で精製して極めて純度の高
いショ糖液とした後、さらにイオン交換樹脂で処理し、
ショ糖を加水分解させて得られる。得られた転化型液糖
の一般成分は、純糖率が３０．０〜４６．２％、還元糖
分が３０．０〜４６．２％、転化率が４０．０〜６０
％、糖度が７４．２〜７６．２％、好ましくは純糖率が
３５．７〜４０．３％、還元糖分が３５．７〜４０．３
％、転化率が４６．０〜５５．０％、糖度が７４．７〜
７５．７％であり、一般に、液剤全量に対して５〜３０
重量％、好ましくは、１５〜２５重量％の配合比率で使
用される。本発明においては、特に限定するものではな
いが、転化型液糖のショ糖、ブドウ糖、果糖の混合液の
比率が、ビタミンＢ群またはその誘導体の苦味のマスキ
ングに関係するものと推測され、ショ糖、ブドウ糖、果
糖の比率は、ショ糖３０〜６０％、ブドウ糖１５〜３０
％、果糖１５〜３０％、好ましくはショ糖４０〜６０
％、ブドウ糖２０〜３０％、果糖２０〜３０％であるこ
とが望ましく、さらに好ましくは、約５０％転化し転化
糖（ショ糖を分解して得られるブドウ糖と果糖の混合
物）とショ糖の等量組成液糖が望ましい。また、ショ
糖：果糖：ブドウ糖の比率は、１．３〜３．１：１：１
が好ましく、さらに好ましくは、ショ糖：果糖：ブドウ
糖の比率が、ほぼ２：１：１の液糖である。このような
転化型液糖は、市販のものが入手可能であり、例えば、
台糖株式会社の転化型液糖ＤＬＩとして市販されている
液糖が使用できる。The invert type liquid sugar used in the present invention is produced from raw sugar obtained by condensing sugarcane and beet juice, crystallizing sucrose, and taking out the sugar. After dissolving the crude sugar and purifying it with activated carbon (bone charcoal) or an ion-exchange resin to obtain an extremely pure sucrose solution, it is further treated with an ion-exchange resin,
Obtained by hydrolyzing sucrose. The general components of the obtained converted liquid sugar have a pure sugar ratio of 30.0 to 46.2%, a reducing sugar content of 30.0 to 46.2%, and a conversion ratio of 40.0 to 60.
%, A sugar content of 74.2 to 76.2%, preferably a pure sugar ratio of 35.7 to 40.3%, and a reducing sugar content of 35.7 to 40.3.
%, The conversion is 46.0-55.0%, and the sugar content is 74.7-
75.7%, generally 5 to 30% based on the total amount of the liquid preparation.
% By weight, preferably 15 to 25% by weight. In the present invention, although it is not particularly limited, it is presumed that the ratio of the mixture of sucrose, glucose, and fructose of the invert type liquid sugar is related to the masking of the bitterness of the vitamin B group or a derivative thereof. The ratio of sugar, glucose and fructose is 30-60% for sucrose and 15-30 for glucose.
%, Fructose 15-30%, preferably sucrose 40-60
%, Glucose 20-30%, and fructose 20-30%, more preferably, about 50% invert sugar (a mixture of glucose and fructose obtained by decomposing sucrose) and sucrose. A liquid sugar composition is desirable. In addition, the ratio of sucrose: fructose: glucose is 1.3 to 3.1: 1: 1.
More preferably, it is liquid sugar having a ratio of sucrose: fructose: glucose of about 2: 1: 1. Such invert type liquid sugar is commercially available, for example,
Liquid sugar commercially available as invert type liquid sugar DLI from Taisu Corporation can be used.
【０００７】本発明により苦味を有するビタミンＢ群ま
たはその誘導体は転化型液糖のみで苦味をマスキングす
ることができるが、転化型液糖以外の甘味剤を併用して
もよい。このような甘味剤としては、砂糖、果糖、ブド
ウ糖、麦芽糖、液糖、果糖ブドウ糖液糖、ブドウ糖果糖
液糖、トレハロース、パラチノース、マルチトール、ソ
ルビトール、パラチニット、エリスリトール、キシリト
ール、ソーマチン、シュクラロース、ステビア抽出精製
物などが挙げられる。According to the present invention, the vitamin B group having a bitter taste or a derivative thereof can mask bitterness only with invert type liquid sugar, but a sweetener other than invert type liquid sugar may be used in combination. Such sweeteners include sugar, fructose, glucose, maltose, liquid sugar, fructose dextrose liquid sugar, glucose fructose liquid sugar, trehalose, palatinose, maltitol, sorbitol, palatinit, erythritol, xylitol, thaumatin, sucralose, stevia. Extracted and purified products are exemplified.
【０００８】本発明の内服用液剤における、苦味を有す
るビタミンＢ群またはその誘導体の配合量は、好ましく
は、転化型液糖１重量部に対して０．０００１〜０．０
０２重量部、より好ましくは、０．０００１〜０．００
１重量部である。The amount of the vitamin B group having a bitter taste or a derivative thereof in the liquid preparation for internal use of the present invention is preferably 0.0001 to 0.0
02 parts by weight, more preferably 0.0001 to 0.00
1 part by weight.
【０００９】本発明の液剤は、風味の点からｐＨ２〜７
の範囲が好ましく、ｐＨ２．５〜６．５の範囲がさらに
好ましい。ｐＨがこの範囲を外れると、ビタミンＢ群ま
たはその誘導体の安定性に影響がある。The liquid preparation of the present invention has a pH of 2 to 7 in terms of flavor.
Is preferable, and the range of pH 2.5 to 6.5 is more preferable. If the pH is outside this range, the stability of the B vitamins or derivatives thereof will be affected.
【００１０】本発明の液剤はさらに有機酸または無機酸
の配合により苦味を低減できる。有機酸としてはクエン
酸、ＤＬ−リンゴ酸、酒石酸、乳酸、グルタミン酸、ア
スパラギン酸などをあげることができる。また、無機酸
としては、塩酸、リン酸などをあげることができる。そ
れらのうちで特に好ましいものとしてクエン酸、ＤＬ−
リンゴ酸またはリン酸をあげることができる。The liquid preparation of the present invention can further reduce bitterness by blending an organic acid or an inorganic acid. Examples of the organic acid include citric acid, DL-malic acid, tartaric acid, lactic acid, glutamic acid, aspartic acid, and the like. In addition, examples of the inorganic acid include hydrochloric acid and phosphoric acid. Among them, citric acid and DL-
Malic acid or phosphoric acid can be mentioned.
【００１１】本発明の液剤には上記成分の他、通常液剤
に用いることが可能な成分、例えばアミノエチルスルホ
ン酸、アスパラギン酸、アルギニン、リジン、アスコル
ビン酸、ニコチン酸アミド、ビタミンＡもしくはその誘
導体、ビタミンＥもしくはその誘導体、塩化カルニチ
ン、コンドロイチン硫酸、カフェイン、生薬（ニンジ
ン、トチュウ、ロクジョウ、ケイヒ、ガラナ、シャクヤ
ク、タイソウ、ショウキョウ、カンゾウ、カイバ、ニク
ジュヨウ、ハゲキテン、オウギ、トウキ、ブクリョウ、
ビャクジュツ、ローヤルゼリーなど）、プロピレングリ
コール、保存剤などを配合することができる。[0011] In addition to the above components, the liquid preparation of the present invention may contain other components which can be used usually in liquid preparations, such as aminoethylsulfonic acid, aspartic acid, arginine, lysine, ascorbic acid, nicotinamide, vitamin A or a derivative thereof, Vitamin E or its derivatives, carnitine chloride, chondroitin sulfate, caffeine, herbal medicines (carrot, eucommia, locust, calyx, guarana, peonies, syllium, shokyo, kanzo, kanzo, kiba, citrus, balsam,
(Junction, royal jelly, etc.), propylene glycol, preservatives and the like.
【００１２】本発明の液剤は、所望の成分を混合、溶解
するような常法に従って製造でき、食品、医薬品および
医薬部外品としての内服用液剤とすることができる。The liquid preparation of the present invention can be produced according to a conventional method of mixing and dissolving desired components, and can be used as a liquid preparation for internal use as foods, pharmaceuticals and quasi-drugs.
【００１３】[0013]
【実施例】以下、実施例および比較例をあげて本発明を
さらに詳細に説明する。 実施例１ 塩酸フルスルチアミン ２．５ｍｇ リボフラビン ２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 転化型液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、ろ過後、８０℃で３０秒滅菌
して、試験溶液を得た。The present invention will be described below in more detail with reference to examples and comparative examples. Example 1 Fursultiamine hydrochloride 2.5 mg Riboflavin 2 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Caffeine anhydride 50 mg Citric acid 350 mg DL-malic acid 180 mg Inverted liquid sugar 21.5 g Benzo Sodium acid salt 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount of purified water 100 mL The above components were mixed and dissolved, filtered, and sterilized at 80 ° C. for 30 seconds to obtain a test solution.
【００１４】実施例２ 塩酸フルスルチアミン ５ｍｇ リボフラビン ２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 転化型液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、ろ過後、８０℃で３０秒滅菌
して、試験溶液を得た。Example 2 Fursultiamine hydrochloride 5 mg Riboflavin 2 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Caffeine anhydride 50 mg Citric acid 350 mg DL-malic acid 180 mg Inverted liquid sugar 21.5 g Sodium benzoate 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount of purified water was added and 100 mL. The above components were mixed and dissolved, filtered, and sterilized at 80 ° C. for 30 seconds to obtain a test solution.
【００１５】実施例３ 塩酸フルスルチアミン ２．５ｍｇ リン酸リボフラビンナトリウム ２．５４ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 転化型液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、ろ過後、８０℃で３０秒滅菌
して、試験溶液を得た。Example 3 Fursultiamine hydrochloride 2.5 mg Riboflavin sodium phosphate 2.54 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-aspartate 125 mg Aminoethylsulfonic acid 1000 mg Caffeine anhydride 50 mg Citric acid 350 mg DL-malic acid 180 mg Inverted liquid sugar 21.5 g Sodium benzoate 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount of purified water 100 mL The above components were mixed and dissolved, filtered, and sterilized at 80 ° C. for 30 seconds to obtain a test solution.
【００１６】実施例４ 塩酸フルスルチアミン ２．５ｍｇ リン酸リボフラビンナトリウム １２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 転化型液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、ろ過後、８０℃で３０秒滅菌
して、試験溶液を得た。Example 4 Fursultiamine hydrochloride 2.5 mg Riboflavin sodium phosphate 12 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-aspartate 125 mg Aminoethylsulfonic acid 1000 mg Caffeic anhydride 50 mg Citric acid 350 mg DL-malic acid 180 mg Inverting type Liquid sugar 21.5 g Sodium benzoate 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount of purified water 100 mL The above components were mixed and dissolved, filtered, and sterilized at 80 ° C. for 30 seconds to obtain a test solution.
【００１７】実施例５ 塩酸フルスルチアミン ５ｍｇ リン酸リボフラビンナトリウム ２．５４ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 転化型液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、ろ過後、８０℃で３０秒滅菌
して、試験溶液を得た。Example 5 Fursultiamine hydrochloride 5 mg Sodium riboflavin phosphate 2.54 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Caffeine anhydride 50 mg Citric acid 350 mg DL-malic acid 180 mg Liquid sugar 21.5 g Sodium benzoate 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount of purified water 100 mL The above components were mixed and dissolved, filtered, and sterilized at 80 ° C. for 30 seconds to obtain a test solution.
【００１８】実施例６ 塩酸フルスルチアミン ５ｍｇ リン酸リボフラビンナトリウム １２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 転化型液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、ろ過後、８０℃で３０秒滅菌
して、試験溶液を得た。Example 6 Fursultiamine hydrochloride 5 mg Sodium riboflavin phosphate 12 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Caffeic anhydride 50 mg Citric acid 350 mg DL-malic acid 180 mg Inverted liquid sugar 21.5 g Sodium benzoate 60 mg Ethyl paraoxybenzoate 6 mg Flavor A trace amount of purified water was added and 100 mL The above components were mixed and dissolved, filtered, and sterilized at 80 ° C. for 30 seconds to obtain a test solution.
【００１９】実施例７ 塩酸フルスルチアミン １７ｍｇ リボフラビン ２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 転化型液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、０．４５μｍのメンブランフ
ィルターでろ過し、試験溶液を得た。Example 7 Fursultiamine hydrochloride 17 mg Riboflavin 2 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Caffeine anhydride 50 mg Citric acid 350 mg DL-malic acid 180 mg Inverted liquid sugar 21.5 g Sodium benzoate 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount of purified water was added and 100 mL The above components were mixed and dissolved, and the mixture was filtered through a 0.45 μm membrane filter to obtain a test solution.
【００２０】実施例８ 塩酸フルスルチアミン ３７ｍｇ リボフラビン ２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 転化型液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、０．４５μｍのメンブランフ
ィルターでろ過し、試験溶液を得た。Example 8 Fursultiamine hydrochloride 37 mg Riboflavin 2 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Caffeine anhydride 50 mg Citric acid 350 mg DL-malic acid 180 mg Inverted liquid sugar 21.5 g Sodium benzoate 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount of purified water was added and 100 mL The above components were mixed and dissolved, and the mixture was filtered through a 0.45 μm membrane filter to obtain a test solution.
【００２１】比較例１ 塩酸フルスルチアミン ２．５ｍｇ リボフラビン ２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 果糖ブドウ糖液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、０．４５μｍのメンブランフ
ィルターでろ過し、試験溶液を得た。Comparative Example 1 Fursultiamine hydrochloride 2.5 mg Riboflavin 2 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Anhydrous caffeine 50 mg Citric acid 350 mg DL-malic acid 180 mg Fructose dextrose liquid sugar 21 0.5 g Sodium benzoate 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount Purified water was added 100 mL The above components were mixed and dissolved, and the mixture was filtered through a 0.45 μm membrane filter to obtain a test solution.
【００２２】比較例２ 塩酸フルスルチアミン ５ｍｇ リボフラビン ２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 果糖ブドウ糖液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、０．４５μｍのメンブランフ
ィルターでろ過し、試験溶液を得た。Comparative Example 2 Fursultiamine hydrochloride 5 mg Riboflavin 2 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Anhydrous caffeine 50 mg Citric acid 350 mg DL-malic acid 180 mg Fructose dextrose liquid sugar 21.5 g Sodium benzoate 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount of purified water was added and 100 mL The above components were mixed and dissolved, and the mixture was filtered through a 0.45 μm membrane filter to obtain a test solution.
【００２３】比較例３ 塩酸フルスルチアミン ２．５ｍｇ リン酸リボフラビンナトリウム ２．５４ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 果糖ブドウ糖液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、０．４５μｍのメンブランフ
ィルターでろ過し、試験溶液を得た。Comparative Example 3 Fursultiamine hydrochloride 2.5 mg Riboflavin sodium phosphate 2.54 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Caffeine anhydride 50 mg Citric acid 350 mg DL-malic acid 180 mg Fructose-glucose liquid sugar 21.5 g Sodium benzoate 60 mg Ethyl parahydroxybenzoate 6 mg Fragrance trace amount of purified water 100 mL The above components were mixed and dissolved, followed by filtration with a 0.45 μm membrane filter to obtain a test solution.
【００２４】比較例４ 塩酸フルスルチアミン ２．５ｍｇ リン酸リボフラビンナトリウム １２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 果糖ブドウ糖液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、０．４５μｍのメンブランフ
ィルターでろ過し、試験溶液を得た。Comparative Example 4 2.5 mg of fursultiamine hydrochloride 12 mg of sodium riboflavin phosphate 10 mg of pyridoxine hydrochloride 25 mg of sodium nicotinamide 125 mg of sodium L-aspartate 1000 mg of anhydrous caffeine 50 mg of citric acid 350 mg of DL-malic acid 180 mg of fructose dextrose Liquid sugar 21.5 g Sodium benzoate 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount Purified water was added and 100 mL The above components were mixed and dissolved, and the mixture was filtered through a 0.45 μm membrane filter to obtain a test solution.
【００２５】比較例５ 塩酸フルスルチアミン ５ｍｇ リン酸リボフラビンナトリウム ２．５４ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 果糖ブドウ糖液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、０．４５μｍのメンブランフ
ィルターでろ過し、試験溶液を得た。Comparative Example 5 Fursultiamine hydrochloride 5 mg Sodium riboflavin phosphate 2.54 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Caffeine anhydride 50 mg Citric acid 350 mg DL-malic acid 180 mg Fructose dextrose Liquid sugar 21.5 g Sodium benzoate 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount Purified water was added and 100 mL The above components were mixed and dissolved, and the mixture was filtered through a 0.45 μm membrane filter to obtain a test solution.
【００２６】比較例６ 塩酸フルスルチアミン ５ｍｇ リン酸リボフラビンナトリウム １２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 果糖ブドウ糖液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、０．４５μｍのメンブランフ
ィルターでろ過し、試験溶液を得た。Comparative Example 6 Fursultiamine hydrochloride 5 mg Sodium riboflavin phosphate 12 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Anhydrous caffeine 50 mg Citric acid 350 mg DL-malic acid 180 mg Fructose dextrose 21.5 g Sodium benzoate 60 mg Ethyl paraoxybenzoate 6 mg Fragrance Trace amount of purified water was added and 100 mL The above components were mixed and dissolved, and the mixture was filtered through a 0.45 μm membrane filter to obtain a test solution.
【００２７】比較例７ 塩酸フルスルチアミン １７ｍｇ リボフラビン ２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 果糖ブドウ糖液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、０．４５μｍのメンブランフ
ィルターでろ過し、試験溶液を得た。Comparative Example 7 Fursultiamine hydrochloride 17 mg Riboflavin 2 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Anhydrous caffeine 50 mg Citric acid 350 mg DL-malic acid 180 mg Fructose dextrose liquid sugar 21.5 g Sodium benzoate 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount of purified water was added and 100 mL The above components were mixed and dissolved, and the mixture was filtered through a 0.45 μm membrane filter to obtain a test solution.
【００２８】比較例８ 塩酸フルスルチアミン １７ｍｇ リボフラビン ２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、０．４５μｍのメンブランフ
ィルターでろ過し、試験溶液を得た。Comparative Example 8 Fursultiamine hydrochloride 17 mg Riboflavin 2 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-Aspartate 125 mg Aminoethylsulfonic acid 1000 mg Caffeine anhydride 50 mg Citric acid 350 mg DL-malic acid 180 mg Liquid sugar 21.5 g Benzoic acid Sodium 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount of purified water 100 mL The above components were mixed and dissolved, and the mixture was filtered through a 0.45 μm membrane filter to obtain a test solution.
【００２９】比較例９ 塩酸フルスルチアミン １７ｍｇ リボフラビン ２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 精製白糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、０．４５μｍのメンブランフ
ィルターでろ過し、試験溶液を得た。Comparative Example 9 Fursultiamine hydrochloride 17 mg Riboflavin 2 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Anhydrous caffeine 50 mg Citric acid 350 mg DL-malic acid 180 mg Purified sucrose 21.5 g Benzoic acid Sodium 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount of purified water 100 mL The above components were mixed and dissolved, and the mixture was filtered through a 0.45 μm membrane filter to obtain a test solution.
【００３０】比較例１０ 塩酸フルスルチアミン ３７ｍｇ リボフラビン ２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 果糖ブドウ糖液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、０．４５μｍのメンブランフ
ィルターでろ過し、試験溶液を得た。Comparative Example 10 Fursultiamine hydrochloride 37 mg Riboflavin 2 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Anhydrous caffeine 50 mg Citric acid 350 mg DL-malic acid 180 mg Fructose dextrose liquid sugar 21.5 g Sodium benzoate 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount of purified water was added and 100 mL The above components were mixed and dissolved, and the mixture was filtered through a 0.45 μm membrane filter to obtain a test solution.
【００３１】比較例１１ 塩酸フルスルチアミン ３７ｍｇ リボフラビン ２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 液糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、０．４５μｍのメンブランフ
ィルターでろ過し、試験溶液を得た。Comparative Example 11 Fursultiamine hydrochloride 37 mg Riboflavin 2 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Anhydrous caffeine 50 mg Citric acid 350 mg DL-malic acid 180 mg Liquid sugar 21.5 g Benzoic acid Sodium 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount of purified water 100 mL The above components were mixed and dissolved, and the mixture was filtered through a 0.45 μm membrane filter to obtain a test solution.
【００３２】比較例１２ 塩酸フルスルチアミン ３７ｍｇ リボフラビン ２ｍｇ 塩酸ピリドキシン １０ｍｇ ニコチン酸アミド ２５ｍｇ Ｌ−アスパラギン酸ナトリウム １２５ｍｇ アミノエチルスルホン酸 １０００ｍｇ 無水カフェイン ５０ｍｇ クエン酸 ３５０ｍｇ ＤＬ−リンゴ酸 １８０ｍｇ 精製白糖 ２１．５ｇ 安息香酸ナトリウム ６０ｍｇ パラオキシ安息香酸エチル ６ｍｇ 香料 微量 精製水 加えて１００ｍＬ 上記各成分を混合溶解し、０．４５μｍのメンブランフ
ィルターでろ過し、試験溶液を得た。Comparative Example 12 Fursultiamine hydrochloride 37 mg Riboflavin 2 mg Pyridoxine hydrochloride 10 mg Nicotinamide 25 mg L-sodium aspartate 125 mg Aminoethylsulfonic acid 1000 mg Anhydrous caffeine 50 mg Citric acid 350 mg DL-malic acid 180 mg Purified sucrose 21.5 g Benzoic acid Sodium 60 mg Ethyl paraoxybenzoate 6 mg Fragrance trace amount of purified water 100 mL The above components were mixed and dissolved, and the mixture was filtered through a 0.45 μm membrane filter to obtain a test solution.
【００３３】苦味に関する官能調査 健康な成人１０人を選択し、苦味に関する官能検査を行
った。官能検査は、各検体の苦味を「非常に苦い」、
「苦い」、「わずかに苦い」、「苦くない」の４段階で
評価した。各被験者が試験する検体の順序は、全てラン
ダムに行った。その結果を表１に示した。Sensory survey on bitterness Ten healthy adults were selected and subjected to a sensory test on bitterness. In the sensory test, the bitterness of each sample was "very bitter",
The evaluation was made on a four-point scale of "bitter,""slightlybitter," and "not bitter." The order of specimens tested by each subject was all random. The results are shown in Table 1.
【００３４】[0034]
【表１】表１．苦味に関する官能検査結果
（単位：人） [Table 1] Sensory test results for bitterness
(Unit: person)
【００３５】表１から明らかなように、比較例では「非
常に苦い」、「苦い」、「わずかに苦い」と評価された
割合が多いのに対して、本発明の実施例では「わずかに
苦い」、「苦くない」の評価であった。As is clear from Table 1, in the comparative examples, the percentages evaluated as “very bitter”, “bitter”, and “slightly bitter” are large, whereas in the examples of the present invention, “slightly bitter”. Bitter "and" not bitter ".
【００３６】[0036]
【発明の効果】本発明の内服用液剤は、苦味を有するビ
タミンＢ群の矯味剤に転化型液糖を配合することによ
り、その苦味を低減して、医薬品および医薬部外品とし
て経口的に服用しやすくした。EFFECTS OF THE INVENTION The liquid preparation for internal use according to the present invention reduces the bitterness by blending an invert type liquid sugar with a flavoring agent of the vitamin B group having bitterness, and is orally used as a drug or a quasi-drug. Easy to take.
───────────────────────────────────────────────────── フロントページの続き (51)Int.Cl.7 識別記号 ＦＩ テーマコート゛(参考） Ａ６１Ｋ 47/02 Ａ６１Ｋ 47/02 47/12 47/12 47/26 47/26 Ａ６１Ｐ 3/02 １０４ Ａ６１Ｐ 3/02 １０４ (72)発明者 木村 憲生 奈良県北葛城郡広陵町馬見南２丁目６番18 号 Ｆターム(参考） 4C076 AA12 BB01 CC22 DD22Z DD41Z DD67T FF52 FF61 4C086 AA01 AA02 BC18 BC83 CB09 DA39 MA02 MA05 MA08 MA17 MA52 NA09 ZC24 ──────────────────────────────────────────────────続 き Continued on the front page (51) Int.Cl. 7 Identification symbol FI Theme coat ゛ (Reference) A61K 47/02 A61K 47/02 47/12 47/12 47/26 47/26 A61P 3/02 104 A61P 3 / 02 104 (72) Inventor Norio Kimura 2-6-18 Uminamiminami, Koryo-cho, Kitakatsuragi-gun, Nara Prefecture F-term (reference) NA09 ZC24
Claims (7)
た液剤において、転化型液糖を配合することにより苦味
が低減された内服用液剤。1. A liquid preparation containing a vitamin B group or a derivative thereof, wherein bitterness is reduced by mixing an invert type liquid sugar.
ミンおよびその誘導体、リボフラビンおよびその誘導
体、ピリドキシンおよびその誘導体、ビタミンＢ１２お
よびその誘導体ならびにそれらの薬学的に許容される塩
から選択される１種または２種以上のものである請求項
１記載の内服用液剤。Wherein the vitamin B group or derivatives thereof, thiamine and its derivatives, riboflavin and its derivatives, pyridoxine and its derivatives, vitamin B 12 and derivatives thereof, and one selected from those pharmaceutically acceptable salts Or the liquid preparation for internal use according to claim 1, which is two or more kinds.
ン、その誘導体またはその薬学的に許容される塩から選
択される請求項１記載の内服用液剤。3. The liquid preparation for internal use according to claim 1, wherein the vitamin B group or a derivative thereof is selected from thiamine, a derivative thereof or a pharmaceutically acceptable salt thereof.
載の内服用液剤。4. The liquid preparation for internal use according to claim 1, which comprises fursultiamine.
て５〜３０重量％である請求項１〜４いずれか１項記載
の内服用液剤。5. The liquid preparation for internal use according to claim 1, wherein the compounding ratio of the invertable liquid sugar is 5 to 30% by weight based on the total amount of the liquid preparation.
１〜５いずれか１項記載の内服用液剤。6. The liquid preparation for internal use according to claim 1, wherein the pH of the liquid preparation is in the range of 2 to 7.
求項１〜６のいずれか１項記載の内服用液剤。7. The liquid preparation for internal use according to claim 1, further comprising an organic acid or an inorganic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002040132A JP4248795B2 (en) | 2001-02-23 | 2002-02-18 | Liquid for internal use |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001048258 | 2001-02-23 | ||
| JP2001-48258 | 2001-02-23 | ||
| JP2002040132A JP4248795B2 (en) | 2001-02-23 | 2002-02-18 | Liquid for internal use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002322062A true JP2002322062A (en) | 2002-11-08 |
| JP4248795B2 JP4248795B2 (en) | 2009-04-02 |
Family
ID=37488909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002040132A Expired - Lifetime JP4248795B2 (en) | 2001-02-23 | 2002-02-18 | Liquid for internal use |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP4248795B2 (en) |
| KR (1) | KR100907201B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009501536A (en) * | 2005-07-18 | 2009-01-22 | ズートツッカー アクチェンゲゼルシャフト マンハイム／オクセンフルト | Hypoglycemic mixture |
| JP2012126714A (en) * | 2010-11-26 | 2012-07-05 | Daiichi Sankyo Healthcare Co Ltd | Pharmaceutical liquid formulation composition |
| WO2020237340A1 (en) * | 2019-05-31 | 2020-12-03 | Rischbieter Ivo | High-energy food supplement based on inverted sugars and ergogenic products for use in physical activity and method for producing same |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020067832A1 (en) * | 2018-09-28 | 2020-04-02 | 경북대학교 산학협력단 | Composition, comprising thiamine derivative, for prevention or treatment of hypercortisolemia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2629985B1 (en) * | 1988-04-14 | 1994-01-21 | Roussel Uclaf | APPLICATION AS LOW-CALORIC SUGAR PRODUCTS OF FRUCTOSYLATED OLIGOSACCHARIDES AND FOODS, DIETETIC PRODUCTS AND BEVERAGES CONTAINING THEM |
| JPH054921A (en) * | 1990-11-19 | 1993-01-14 | Kanebo Ltd | Vitamin b-containing oral solution agent |
| US5415885A (en) * | 1994-03-25 | 1995-05-16 | The Sweetenbetter Company | Product and process of making a nutritious malt containing soft drink |
-
2002
- 2002-02-18 JP JP2002040132A patent/JP4248795B2/en not_active Expired - Lifetime
- 2002-02-22 KR KR1020020009624A patent/KR100907201B1/en active IP Right Grant
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009501536A (en) * | 2005-07-18 | 2009-01-22 | ズートツッカー アクチェンゲゼルシャフト マンハイム／オクセンフルト | Hypoglycemic mixture |
| JP2012126714A (en) * | 2010-11-26 | 2012-07-05 | Daiichi Sankyo Healthcare Co Ltd | Pharmaceutical liquid formulation composition |
| WO2020237340A1 (en) * | 2019-05-31 | 2020-12-03 | Rischbieter Ivo | High-energy food supplement based on inverted sugars and ergogenic products for use in physical activity and method for producing same |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100907201B1 (en) | 2009-07-10 |
| KR20020069171A (en) | 2002-08-29 |
| JP4248795B2 (en) | 2009-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4051717B2 (en) | Biotin-containing oral solution | |
| KR101490721B1 (en) | Liquid Formulation for Deferiprone With Palatable Taste | |
| KR100472590B1 (en) | Oral Intake Solution | |
| JPH08169831A (en) | Agent for promoting metabolism of alcohol in body and its production | |
| JP4955287B2 (en) | Paeoniflorin-containing jelly preparation | |
| JP4190769B2 (en) | Oral liquid composition | |
| JP2002363105A (en) | Method for masking unpleasant taste and solution for oral administration | |
| JP3805646B2 (en) | Pharmaceutical solution | |
| JP2002322062A (en) | Liquid preparation for oral administration | |
| JP4403590B2 (en) | Vitamin B1 combination liquid | |
| JP2004161679A (en) | Liquid preparation for internal use | |
| KR102313511B1 (en) | Preparation for relieving hangover comprising Curcumin | |
| JP4373649B2 (en) | Oral solution | |
| JP2004175672A (en) | Oral liquid agent containing glycyrrhizinic acid | |
| JP3968797B2 (en) | Vitamin B1 derivative-containing liquid composition | |
| JP2976162B2 (en) | Stable multivitamin oral solution | |
| JP4216916B2 (en) | Drinking liquid composition | |
| JPH09286724A (en) | Liquid stablizer for oral administration | |
| JP2006131625A (en) | Isosorbid preparation improved in taste quality | |
| WO2011148794A1 (en) | Dimemorfan-containing liquid preparation for internal administration | |
| KR101297354B1 (en) | Stable and taste masking syrup composition of transparent solution comprising Dexibuprofen | |
| JPH09286723A (en) | Improved oral solution | |
| JP2012153623A (en) | Bofutsushosan-containing composition | |
| RU2484842C2 (en) | Agent possessing general tonic, adaptogenic and immunity decrease preventing action, and method for preparing it | |
| JP5298526B2 (en) | Composition for internal use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040803 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080527 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080826 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081010 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081016 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081121 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081216 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090114 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120123 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4248795 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120123 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130123 Year of fee payment: 4 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130123 Year of fee payment: 4 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140123 Year of fee payment: 5 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |